Takeda completes sale of select otc and non-core assets to orifarm

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to orifarm group (“orifarm”) for a total value of up to $670 million usd. the portfolio includes approximately 130 over-the-counter (otc) and prescription pharmaceutical products sold in europe, and two manufacturing sites located in denmark and poland. this divestment agreement was first announced i
TAK Ratings Summary
TAK Quant Ranking